AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04654013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
Study NCT04284254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Plasmablasts
Description: Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~* Dose Level 1: 5 x 10e7 cells/kg on Day 0~* Dose Level 2: 1 x 10e8 cells/kg on Day 0~* Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~- Maximum Tolerated Dose (MTD) established in Phase I
Study NCT05789966 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Risk Estimate+Health Coaching
Description: The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.
Study NCT05789966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genetic Risk Estimate + Fitbit Functions+Health Coaching
Description: Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well
Study NCT06521177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Serum and Glove
Description: Participants will apply the Hand Serum to both hands daily for 8 weeks. During Weeks 7-8, participants will also wear a glove on one hand. The intervention aims to improve skin health and appearance on the hands, assessed through questionnaires and expert skin grading.
Study NCT05376501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: 8 mg Astaxanthin per capsule, taken once a day with meal
Study NCT05376501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Modified food starch
Study NCT06492083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine hot bag
Description: traditional Chinese medicine hot bag
Study NCT05867381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA filtration
Description: HEPA filters with the capacity to reduce PM2.5 levels
Study NCT05867381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham filtration
Description: Sham filtration use the same appearance of air purifier but with HEPA filter removed.
Study NCT05327582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered intravenously, 1000 mg on day 1 in a 3-week cycle
Study NCT05327582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered orally, 8mg/d once daily in a 3-week cycle
Study NCT05327582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
Study NCT05273762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowTriever
Description: Mechanical thrombectomy for pulmonary embolism
Study NCT05567081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
Study NCT05567081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
Study NCT06138210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exosomes derived from human induced pluripotent stem cell for injection
Description: Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).
Study NCT06138210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a placebo of exosomes derived from human induced pluripotent stem cell for injection
Description: Exosomes placebo, 3.0ml
Study NCT04352673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Elbow flexion and extension strength measurements using a hand-held dynamometer
Description: Elbow flexion and extension strength of the participants will be measured in both arms in the supine, prone, and sitting positions using a hand-held dynamometer.
Study NCT05804812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter therapy
Description: Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
Study NCT04624113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Epizyme will supply the study agent, which will be provided free of charge to the patient.
Study NCT04624113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is commercially available
Study NCT06114680 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CochSyn test prototype
Description: The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.
Study NCT06114680 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Universal Smart Box (USB)
Description: Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
Study NCT06401707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel
Description: Perampanel is a non-competitive AMPA glutamate receptor antagonist.
Study NCT06401707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05337761 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer-led training on lifejacket wear
Description: Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
Study NCT05337761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led training on lifejacket wear
Description: Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
Study NCT05211934 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04844216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® L Lidocaine
Description: An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
Study NCT04844216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
Study NCT05286892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes LIVE JustICE
Description: Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
Study NCT05286892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Education
Description: See control group description above
Study NCT04159467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: 4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
Study NCT04159467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: 4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
Study NCT05267665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family Intervention (BFI)
Description: A 2-session psychoeducational and skills-based family intervention.
Study NCT04119648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS-4Kids
Description: The Collaborative Assessment and Management of Suicidality (CAMS-Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.
Study NCT05507099 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspirate, Lipoaspirate Concentrate
Description: Autologous Cell Therapy.
Study NCT05932888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLM3003
Description: 1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
Study NCT05932888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QLM3003 Placebo
Description: 1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
Study NCT05556655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
Study NCT05556655 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
Study NCT05062096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples at each protocol visit, T and NK cell analysis
Study NCT05062096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: Biopsy of the skin lesion (optional)
Study NCT05734261 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway Oscillation System
Description: After each methacholine dose administred, respiratory function will be measured by forced oscillation
Study NCT06054386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Bias Modification Training (ABMT)
Description: The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to positive or neutral stimuli. In the training, after a pair of facial stimuli (e.g., threatening-neutral, neutral-neutral) are presented, a left or right arrow appears in one of the location. Participants are instructed to press the button in the correct direction as quickly and accurately as possible.
Study NCT06054386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Attention Control Training
Description: The general attention control training aimed to improve participants' general attention control ability by asking them to press a left or right arrow in the correct direction. The basic design of attention control training is the same as the ABMT, but the attention control training does not aim to alter the direction of attention toward or away from certain stimuli.
Study NCT05571111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302
Description: Subcutaneous injection as a single dose. 3 different doses
Study NCT05571111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovitrelle
Description: Subcutaneous injection as a single dose. 250 µg (0.5 mL)
Study NCT05571111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novarel
Description: Subcutaneous injection as a single dose. 10,000 IU (1 mL)
Study NCT06496451 — intervention group
Intervention type: OTHER
Intervention: Spinal tap for CSF collection
Description: A spinal tap will be done on you by your choice of bedside or in the interventional radiology (IR) suite in the Shands (Neuromedicine) hospital. This procedure will be done by trained technicians under medical supervision or the principal investigator. Local anesthesia will be used to numb the site of injection on your back. We plan to collect about 4 tablespoons of spinal fluid.
Study NCT06496451 — intervention group
Intervention type: OTHER
Intervention: Venipuncture for blood sample
Description: a sample of blood (approximately 4-5 tablespoonfuls) will be collected
Study NCT06265831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-fan application to the face
Description: Hand fan application is one of the applications recommended in managing dyspnea in evidence-based guidelines. Hand fan application effectively reduces shortness of breath by stimulating cold airflow to the 2nd and 3rd trigeminal nerve branches, mucosa, and skin.
Study NCT04824807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga classes included a progression of low-impact, modified poses, stretching and isometric exercises focused on the shoulders, arms, and chest, and meditation. Breathing and poses to drain the lymphatic system were incorporated throughout the yoga practice to assist with lymphatic flow.~Exercises: sitting down badrasana, ardha navasana, dhanurasan, setu bandhasana, Urdhva Dhanurasana, Urdhvamukha Svanasana, Virabhadrasana, Warrior Virasana, Supta Virasana, Surya Namaskar, Mayurasana, Padmasana, Bharadvajasana.
Study NCT04824807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates
Description: before starting the clinical Pilates exercise program, the patients were trained on Pilates exercises and postures. During training, the patients were taught how to create lumbopelvic stability (core stabilization), which is the basis for Pilates exercises, and spinal stabilization and appropriate posture techniques.~Exercises: cork screw, toy soldier, kleopatra, the saw,breast stroke preparation, swimming, diamond press - arm openings, scapula isolations, open book, scissors, shoulder bridge.
Study NCT04824807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An educational booklet
Description: Only educational booklets will be given to the control group
Study NCT04824807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: An educational booklet
Description: Only educational booklets will be given to the control group
Study NCT05098080 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hutrukin
Description: Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.
Study NCT05098080 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for Hutrukin IV push.
Study NCT04534751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen + PCC
Description: Patients randomized to the intervention group will receive 4g of Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs, if requested.~If a third MHP pack is required, and thereafter, FC will be administered if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units).
Study NCT04534751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Plasma
Description: 4U FP will be released as part of the first and second MHP packs.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units).~Patients randomized to the control group may receive FC if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods. FC dosing in MHP packs 3 and above will be site-specific and at the discretion of the treating clinician.
Study NCT06171893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wavy stress application
Description: The intervention consists of the application named Wavy. Wavy uses artificial intelligence and the user's feedback to detect stress increasingly more efficient over time. This provides not only real-time feedback on an individual's stress level but also helps the patient to calm down using music guided relaxation. It does so with a music filter, allowing the participant to listen to music where the stress level determines the quality of the music.~Thus, relaxing is rewarded by improving the experience. In this process, implicit learning is used to establish a habit of getting better at recognising increased stress levels and getting familiar with reducing stress levels more and more effectively.
Study NCT04991714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactisole
Description: sweet taste inhibitor (decreases sweetness)
Study NCT04991714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebaudioside M
Description: Sweetener (increases sweetness)
Study NCT04991714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 10% Sucrose corresponding to a regular soft drink
Study NCT05696951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transamine 200mg iv
Description: In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
Study NCT05696951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transamine 200mg iv
Description: In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
Study NCT05573243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bonding strategies
Description: The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
Study NCT05656196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese herbal tea VGH-DESJS-1
Description: Chinese herbal tea VGH-DESJS-1.
Study NCT05858983 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-001 Low Dose
Description: Comparison of different dosages of FT-001